CMS Website open until Sept 1, 2008 for comments on value of genomic testing for warfarin dosing

Henry I. Bussey, Pharm.D., FCCP, FAHA
August, 2008

The merits of genomic testing to assist in selecting a warfarin dose have been hotly debated in recent months. Now CMS is soliciting input on whether the available data warrant use (and/or coverage) of such testing.

You can read more and submit your comments to Medicare at https://www.cms.hhs.gov/mcd/
viewtrackingsheet.asp?from2=viewtrackingsheet.asp&id=224&. To get to the comments page, click the orange Comment button in the upper right-hand section of the page.

Our intent is to make you aware of this opportunity to submit your views; ClotCare does NOT seek to alter your opinion. However, an examination of this issue is available on ClotCare at www.clotcare.com/clotcare/warfaringenetictesting.aspx and the Anticoagulation Forum website at http://acforum.org/iframe_pages/pdf/July07-newsletter-final.pdf.